Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377676 | 0.85 | HTR6 (0.37) | HTR6DRD4SIGMAR1DRD3TMEM97 | |
| SCHEMBL31377731 | 0.81 | GRM2 (0.36) | HTR6DRD4SIGMAR1DRD3TMEM97 | |
| SCHEMBL30112223 | 0.81 | BRD4 (0.48) | SLC6A4MAOBSRD5A1BRD4 | |
| SCHEMBL5206057 | 0.80 | MAOB (0.42) | SLC6A4MAOAMAOBBRD4 | |
| SCHEMBL22516964 | 0.79 | SLC6A4 (0.43) | SLC6A4 | |
| SCHEMBL31377710 | 0.76 | ALDH1A1 (0.42) | HTR6DRD4SIGMAR1DRD3TMEM97 | |
| SCHEMBL31377808 | 0.74 | MAOB (0.41) | MAOAMAOB | |
| SCHEMBL22517064 | 0.72 | TACR1 (0.43) | — | |
| SCHEMBL20241215 | 0.70 | BRD4 (0.43) | DRD3MAOAMAOBBRD4 | |
| SCHEMBL14567304 | 0.70 | SLC6A4 (0.44) | SLC6A4SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | SLC6A4 2422/4885HTR6 412/4885DRD4 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.